"The vision here at Creighton to do the preclinical, otoprotective work and the collaborative environment here is absolutely phenomenal and central to translational medicine.”
- Dr. Peter Steyger
- Dr. Peter Steyger
"Translational Hearing Center Awarded Largest NIH Grant In Creighton University History"
|
Dr. Peter Steyger is the Director of the Dr. Richard J. Bellucci Translational Hearing Center
in Creighton University's Biomedical Sciences Department in the School of Medicine.
His laboratory is primarily funded by NIH-NIDCD to identify the mechanisms by which circulating ototoxic drugs cross the blood-labyrinth barrier into the cochlear fluids and enter sensory hair cells to induce cytotoxicity that leads to permanent hearing loss and deafness. Dr. Steyger's focus is to characterize the trafficking mechanisms utilized by aminoglycoside antibiotics,
using both immunolabeled and fluorescently-tagged gentamicin.
His lab recently identified that inflammation and inflammatory mediators enhance cochlear uptake of aminoglycosides and exacerbates aminoglycoside-induced hearing loss. Much of the expertise gained in understanding the mechanisms of aminoglycoside hearing loss have led to analogous studies for the cochleototoxic anti-cancer drug, cisplatin, and further improve our understanding of the mechanisms of cisplatin-induced ototoxicity. More recently, they have initiated human studies to determine if clinical evidence of systemic inflammation increases the risk of hearing loss in sick neonates dosed with aminoglycosides, and whether subpopulations of subjects with cystic fibrosis have a greater genetic susceptibility (or resistance) to aminoglycoside-induced ototoxicity.
in Creighton University's Biomedical Sciences Department in the School of Medicine.
His laboratory is primarily funded by NIH-NIDCD to identify the mechanisms by which circulating ototoxic drugs cross the blood-labyrinth barrier into the cochlear fluids and enter sensory hair cells to induce cytotoxicity that leads to permanent hearing loss and deafness. Dr. Steyger's focus is to characterize the trafficking mechanisms utilized by aminoglycoside antibiotics,
using both immunolabeled and fluorescently-tagged gentamicin.
His lab recently identified that inflammation and inflammatory mediators enhance cochlear uptake of aminoglycosides and exacerbates aminoglycoside-induced hearing loss. Much of the expertise gained in understanding the mechanisms of aminoglycoside hearing loss have led to analogous studies for the cochleototoxic anti-cancer drug, cisplatin, and further improve our understanding of the mechanisms of cisplatin-induced ototoxicity. More recently, they have initiated human studies to determine if clinical evidence of systemic inflammation increases the risk of hearing loss in sick neonates dosed with aminoglycosides, and whether subpopulations of subjects with cystic fibrosis have a greater genetic susceptibility (or resistance) to aminoglycoside-induced ototoxicity.
Learn more about the Dr. Richard J. Bellucci Translational Hearing Center at Creighton University's
School of Medicine |
|
Creighton's Hearing Center Named After Pioneering Alumnus "The newly named Dr. Richard J. Bellucci Translational Hearing Center continues the legacy of its legendary namesake..." |
Sponsored by the Bellucci DePaoli Family Foundation. Alumnus Dr. Richard J. Bellucci, MD '42 was a national leader in the utilization of ear surgical techniques to treat conductive hearing loss. Questions? Email [email protected]. |